Localized initiatives & global virtual institutes

Stina GestreliusMedicon Valley AcademySweden-Denmark

April 2005

Medicon Valley

26 hospitals6 science parks14 universities

>100 medtech companies>100 biotech companies>50 pharma companiesCROs, service providers, investors36.000 employees (29’+7’)60 % of DK+S bio/med. exports

3.2 million inhabitants140.000 students6.000 bio-R&D

*Copenhagen University (35,000 students)*Danish Technical University*Danish Pharmaceutical University*Danish Veterinary & Agricultural University*Roskilde University CenterCopenhagen Business SchoolCopenhagen IT UniversityDanish Educational UniversityDanish Library UniversityDanish Arts and Architecture School

*Lund University (35,000 students)*Malmö University College*Swedish Agricultural UniversityKristianstad University College

* Denotes bio/med/tech research

Universities in Øresund Region

Number of publications and citations in biotech (1997-2001)

PublicationsCitationsBoston 37,000 185,000Bay Area (US) 27,500 140,000Paris 27,000 85,000Medicon Valley 15,000 52,000Cambridge area 15,000 51,000 Stockholm 14,000 49,000Munich 12,000 25,000

.

The Boston Consulting Group, 2002

Medicon Valley

0

500

1000

1500

2000

2500

3000

3500

1997 1998 1999 2000 2001 2002

Year

SC

I pa

pe

rs

MV KL

SU OX

Strategic Report

Number of biotech publications

Karolinska Institutet

Stanford

Oxford

City University of London, 2004

Scientific Excellence•Diabetes •Neuroscience •Oncology•Inflammation•Infection control

•Stemcell research•Nanotechnology•Proteomics

Medicon Valley

Blockbusters

Cipramil (antidepressive)

Lundbeck

NovoPen (insulin)

Novo Nordisk

Turbuhaler (powder inhalator)

AstraZeneca, Lund

Research infrastructure investments

•BMC (Lund)

Bio Medical Center

•CRC (Malmö)

Clinical Research Center

•BRIC (Copenhagen)

Biotech Research and Innovation Center

Total investments 3-4 billion SEK

• SWEGENE (Lund)Postgenomic RT Programme in South Western Sweden

Proteomics

Microarray

Cryo-EM

Genomic EcologyUniversity Hospital

BMC

IdeonSciencePark

MAX-lab

Transgenic core facility

Bioinformatics

Chemical Centre

LTH

Sony Ericsson

Gambro

Active Biotech

Astra Zeneca

500 m

School of Economics

LUND North Campus AreaESS?

SymbionScience ParkCopenhagen*85 enterprises in Symbion (+BRIC)*Main competences are IT and Biotechnology Bio: ACADIA, AH Diagnostics, Astion, A-Syntese, BioMonitor, Cartificial, Chempaq, Ciphergen, CMC, Colotech, CopyGene, Direct Haler, ENKAM, Evolva, Genesto, HemeBiotech, KLIFO, Leucotech, Lica, LivingCell, MedChem, NatImmune, Nordic Bone, Pipeline Biotech, Schafer, TAG, Topo

.

Medicon Valley Academy

Initiative 1995 from universitiesand big pharma companies

2000: Private membership basednon profit organisation Universities, hospitals &companies (250 members)

2 nations – 2 systems

Founding membersLU: Per Belfrage (chair)KU: Søren BuusSkåne: Ingvar WibergK Amt: Joost NielsenH:S: Helle UlrichsenFredr Amt: Anders Kyst

ElectedMikael Ørum, Ventac PartnersSibylle Moltzen Lenz, LundbeckBørge Diderichsen, NovoNordiskLars Hedbys, SynarcLars-Erik Arvidsson, AstraZenecaCristina Glad, BioInventSven Frøkjær, DFUSøren Brunak, DTUMogens Pedersen, Coloplast

Cluster Dynamics

ConceptionFormation

GrowthMaturity

Knowledge Creation Technology Transfer

CommercialisationClusters & Networks

Industry R & D

Public & PrivateFunding

Universities &Research Institutions

Patents &Licences

Proof of ConceptTesting

Incubation/Research Parks

Venture Capital

Clinical Trials

Collaboration/Partnerships

RegulatoryApproval

Business Planning

Job Creation

IPOs /gazellesLabour MarketProduct Pipeline

Economicsof Scale

RegulatoryEnvironment

M&A Activity

IndustryPartnerships

Upstream

Midstream

Downstream

POST-DOC programme (9)•system biology•nanobiotechnology•3D-modelling of molecular structures

Cooperation between Ø-forsk, Øresund IT Academy and Medicon Valley Academy

.

Medicon Valley Academy PhD programme (12)PhD students co-financed betweencompanies and HUR/Region Skåne

• Bioinformatics • Biostatistics• Children and Diabetes• 3D-modelling of Proteins• Food versus Drugs (2)• Hospital laboratory of the future• Infectious diseases• Inflammation• IT-competent hospitals• Medical Imaging (2)• Nanobiotechnology• Neuroscience• Oncology• Point-of-care testing• Proteomics (2)• Stem cells therapeutic perspectives• Therapeutic medical devices

MVA Networks

• Biostatistics• Business & Start-ups• Cancer• Diabetes• Drug Development• Food versus Drugs• Hospital Management• Human Resources• Hepatocyte User Group• Mass Spectroscopy• Technology Transfer

Strategic Report on Research in prep.

Future research strategies and implications for Medicon ValleyCopenhagen 30 March 2005  

Bertil Andersson, European Science Foundation, Strasbourg

Bruno Hansen, Danish Council for Research Policy, Copenhagen

Staffan Normark, Swedish Foundation for Strategic Research, Stockholm

Kristian Helin, Biotech Research & Innovation Center (BRIC), Copenhagen 

Other: Danish governmental declaration Feb 2005 Swedish research bill March 2005Six Countries Programme ConferenceEtc.

Commercialization of public research

   Medicon Valley(2002)

 

 Karolinsk

a Institutet

(2003)

 Oxford

University

(2003)

 Stanford Universit

y (2002) 

INPUT 

       

 Research spend per year (mill. €)

 300

 300

 200-250

 400

 OUTPUT

 

       

 Publications 

 3200

 

 2800

 1900

 2000

 Invention disclosures

 180

 

 100

 150

 315

From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

1) More commercial know-how into Technology Transfer Organisations

2) Regional TTO cooperation (!)

3) Funding for Proof - of- Concept studies

4) Seed investments across Øresund (!)

5) Tax incentives for the Young Biotech Industry

From BioScience to New Jobs in Medicon Valley - A Medicon Valley Academy Strategic Report

MVA STRATEGIC REPORTS

Innovation Report 2004Recommendations to improve the competitiveness of Medicon Valley

0

5

10

15

20

25

30

1997 1998 1999 2000 2001 2002 2003 2004

New bio/med-tech companies in 2004

BioneerBKG PharmaCytotrackDanChipDermagenDermalcolEssentysMedical Prognosis InstMicromorphNeobioticsNovosenseOncore TherapeuticsPHI PicologyPlug-in MedicalProtista BiotechnologyQuantibactStratoSphere PharmaVibroSense Dynamics

Retrospective

125 new companies since 1997Alt. venture capital, survival rates, IPOs etc.

Regional Guides

Patent Guide (2003) Financing Guide (2004) Drug Development Guide (2005)

Medicon Valley AcademyØresund IT AcademyØresund Food NetworkØresund EnvironmentØresund LogisticsØresund DesignØresund Nano

Development over time95 96 97 98 99 00 01 02 03 04 05

Bio                        

Food              

IT              

Environment              

De-sign          

Logistics          

Nano      

Multimedia      

InterReg projectPrep. Membership organisation

Nordic Research & Innovation

Aims for borderless systems within the Nordic countries

ScanBalt: Network of Networks

PLUS:• BioTop (Berlin)• BioMoBil (Gdansk)• Ebio (Tallinn-Tartu)• Latvia• St. Petersburg

Sunrise Valley

”I think the UK and this region are perfect partners and I would like to see even greater cooperation. I am, therefore, delighted to announce today the establishment of the UK-MVA Challenge Programme. This initiative aims to encourage and facilitate greater co-operation between the UK and the Öresund region in core biotechnology areas such as research and industry. The Challenge Programme seeks to develop world class biotechnology. ..”

Lord Sainsbury, UK Minister of Research and Innovation (Oct. 2004)

Changed dynamics

• Regional integration Denmark - Sweden Researchers/ infrastructure /tech transfer/ investments

• Sectorial integration Academia- Hospital- Industry

• Increased research funding (regional, Nordic, EC)

• Increased awareness of research & innovation

Changed dynamics

• Increased investments, seed and venture capital for start-up companies (E&Y 2004)

• New companies and knowledge intensive jobs

•Increased internationalization incl.regional exchange with the UK

• International companies established in the region (e.g. Biogen Idec)